Overcoming Tech Intimidation
AI Oversight From the Board Seat
In the boardroom, the most expensive response to an AI proposal is not "I do not know." It is a nod from a director who does not.
In Brief
The Problem. Many directors approve artificial intelligence proposals they do not fully grasp, and deference to management's experts replaces scrutiny.
Why It Persists. Admitting ignorance is uncomfortable, and boards often respond by recruiting one technical director, which concentrates understanding in a single seat.
What Boards Should Do. Commit every director to a shared baseline of AI literacy, recruit directors who have led large technology change, and let the chair make basic questions a standing part of the agenda.
Few things are more uncomfortable in a boardroom than admitting ignorance. That reluctance has become a governance problem. As healthcare and life sciences organizations adopt artificial intelligence (AI), many directors nod along to proposals they do not fully grasp, intimidated by the speed of change and the vocabulary of the data scientists presenting to them. This "tech intimidation" creates a gap in oversight and exposes the organization to new strategic, clinical, and legal risks.
My argument is that the remedy is not more technical expertise on the board. It is a board in which every director can apply long-standing governance principles to a new kind of asset, and in which asking a basic question is expected rather than tolerated.
The Gap Is in Application, Not Coding
The issue is not a shortage of directors who can write software. It is a deficit in the ability to apply the principles of governance to an unfamiliar technology. Effective oversight of any major initiative challenges management on four fronts:
- The what: the strategic goal;
- The why: the business case;
- The how: the implementation plan; and
- The when: the timing and the organization's readiness.
With AI, many boards falter on the how. A director may understand that a new patient-messaging assistant is meant to reduce cost. Fewer ask about the lineage of the data the model learned from, the protocol used to test it for fairness and accuracy, or the safeguards that keep it from giving a patient offensive or simply incorrect information. Deference to the chief technology officer's perceived expertise takes over, and the board is effectively captured by the management it is supposed to supervise.
The Numbers Show the Gap
Directors are candid about the problem. In the PwC 2026 survey of about 600 public company directors, 71 percent identified AI as the top skill their boards need to strengthen (Gaskin, 2026). The response has not kept pace. The National Association of Corporate Directors (NACD) found in 2025 that only 18 percent of public company boards had an AI education plan for directors, and only six percent had set metrics for management's AI reporting (National Association of Corporate Directors, 2025).
Nonprofit health systems face a sharper version of the same gap. A 2026 report by The Governance Institute found that only 32 percent of the roughly 1,500 nonprofit and public hospital boards in the United States require continuing education for board service, and less than 0.01 percent of patient revenue goes to board development (Condon, 2026). Boards are discussing AI without the shared foundation they need to question it.
The Board Cannot Outsource Its Duty
A board cannot delegate its fiduciary duty. Relying on management alone to regulate its own use of AI is like asking students to grade their own homework. Management's expertise is necessary, but the board's role is to provide independent scrutiny and to act as the steward of the organization and its stakeholders.
The law makes the point concrete. Under In re Caremark International Inc. Derivative Litigation, 698 A.2d 959 (Del. Ch. 1996), directors must make a good-faith effort to ensure that a reporting system exists. Marchand v. Barnhill, 212 A.3d 805 (Del. 2019), applied that duty with particular force to "mission critical" risks (Zauderer et al., 2023). Clinical decision support and regulatory submissions fit that description. A director who cannot follow management's answer cannot judge whether the reporting system works.
Why One Expert Is Not Enough
Many boards respond by appointing an AI expert. Among Fortune 100 companies, 44 percent cited AI as sought board expertise or in at least one director's biography in 2025, up from 26 percent a year earlier (EY Center for Board Matters, 2025).
Appointing an expert is a helpful step, but it is not a solution. The expert can become a single point of failure. Worse, the expert can become a translator who shields the rest of the board from the necessary work of learning the basics. The duty of oversight belongs to every director, and it cannot be delegated to the one who knows the most.
A Two-Part Remedy
A better approach has two parts. First, the board commits to continuing education for all directors on the strategic, clinical, ethical, and legal implications of AI. Briefings, sessions with outside experts, and workshops all serve, provided they recur and are recorded. In my view, a shared baseline covers five subjects:
- how a model is validated before use and monitored after it;
- what the organization's vendor contracts say about data, model changes, audit rights, and liability;
- which state, federal, and international rules apply, and from what dates;
- how the board will judge whether an AI investment is working; and
- what the minutes should show about the board's own oversight.
Second, the board recruits directors who bring more than technical skill. It looks for people who have led large-scale technology implementation and change management, leaders who have learned that a capable algorithm is of little use without sound data governance, disciplined validation, and a culture that can adapt to it. Experience leading a difficult integration is often worth more in the boardroom than familiarity with the latest model.
The Objection: Directors Are Not Meant to Be Technologists
The strongest objection is that this asks too much. Directors are chosen for judgment, not technical knowledge, and the discipline of "nose in, fingers out" tells them to leave the system to management.
The objection is right about the role and wrong about the remedy. Nothing here asks a director to build or run a model. It asks each director to know enough to frame a question and judge whether the answer is adequate. Boards already expect that fluency in finance: no one asks the audit committee to prepare the statements, but every member must be able to read them.
The Chair Sets the Tone
Overcoming tech intimidation requires a cultural shift, led from the top. The chair should actively invite "naive" questions and make it clear that saying "I do not understand" is the start of a necessary conversation, not a moment of embarrassment. I have found that when the chair asks the first basic question, the room changes, and other directors follow.
Practical habits help. A pre-read can define the technical terms before the meeting. The agenda can reserve time for questions before any vote. Management can be asked, as a standing rule, to explain each AI proposal in plain language. The aim is to move the boardroom from passive approval to skeptical stewardship. A basic question costs a few minutes. An unasked one can cost far more.
For the Board
- Does every director, not only one, have the baseline knowledge to question an AI proposal on the what, the why, the how, and the when?
- What is our education plan for directors this year, who owns it, and is it recorded?
- When we last recruited a director, did we weigh experience leading large technology change as well as technical knowledge?
- Does our board pack explain AI proposals in plain language, with time for questions before a vote?
- When did a director last say "I do not understand" in a meeting, and what happened next?
To give your directors a shared foundation through the Board Readiness Workshop, book a conversation with Avancer.
References
Condon, A. (2026, April 27). Health system governance is falling behind: 8 things to know. Becker's Hospital Review. https://www.beckershospitalreview.com/hospital-management-administration/health-system-governance-is-falling-behind-8-things-to-know/
EY Center for Board Matters. (2025, October). Cyber and AI oversight disclosures: What companies shared in 2025. Ernst and Young. https://www.ey.com/content/dam/ey-unified-site/ey-com/pt-br/campaigns/board-matters/documents/ey-cbm-cyber-and-ai-oversight-disclosures-2025-3.pdf
Gaskin, J. L. (2026, September 23). Boards say they need more from management on AI. Corporate Compliance Insights. https://www.corporatecomplianceinsights.com/boards-say-they-need-more-from-management-ai/
National Association of Corporate Directors. (2025). AI oversight activities conducted by the board [Data table]. 2025 Public Company Board Practices and Oversight Survey. Retrieved October 21, 2026, from https://www.nacdonline.org/all-governance/governance-resources/governance-surveys/surveys-benchmarking/bpo-tables/ai-oversight-activities-conducted-by-the-board
Zauderer, F. M., Monteleone, J. P., & Fenichel, A. H. (2023, August). Guest post: Board oversight duties, recent adventures in the Delaware Chancery. The D&O Diary. https://www.dandodiary.com/2023/08/articles/director-and-officer-liability/guest-post-board-oversight-duties-recent-adventures-in-the-delaware-chancery/